Anti-Trastuzumab Type 1 Antibodies

The Type 1 anti-trastuzumab antibodies inhibit the binding of the drug Herceptin to its target, the extracellular domain of the human epidermal growth factor receptor 2 (HER2, also known as ErbB2), and therefore detect free drug. These antibodies are ideal for use in direct and indirect ELISA, pharmacokinetic (PK) bridging assays and to develop and calibrate immune response (IR) assays to measure the anti-drug antibody (ADA) response in patient sera.

Product codes: HCA166, HCA167, HCA168, HCA169, HCA176(P), HCA177(P)

Anti-Trastuzumab Drug/Target Complex Type 3 Antibody

The Type 3 antibody specifically recognizes the drug-target complex. It detects trastuzumab only when it is bound to HER2. This antibody does not bind to free trastuzumab or unbound HER2. It can be used to set up a PK antigen capture assay that avoids the bridging format. In addition, it allows detection of trastuzumab bound to its target in serum as opposed to free trastuzumab.

Product code: HCA263

These recombinant monoclonal antibodies are generated using the HuCAL® phage display antibody library, which results in highly specific and sensitive reagents, ideal for PK assays. Antibodies are fully human, so in full immunoglobulin format they can be used as reference standards for ADA assays. The in vitro production of recombinant antibodies means that there is a consistent, secure supply throughout preclinical development and clinical trials, avoiding the need to develop new reagents.

Human anti-trastuzumab antibodies, product codes HCA166 and HCA168

Figure 1: Anti-trastuzumab antibody antibody, clone AbD18018 (HCA168) was coated at 1 μg/ml on a microtiter plate overnight. After washing and blocking with 5% BSA in PBST, trastuzumab in the given concentrations was added in PBST plus 10% human serum. Detection was performed by HRP conjugated anti-trastuzumab antibody, clone AbD16712 (HCA166)*, at a concentration of 4 µg/ml in HISPEC assay diluent, plus QuantaBlu™ fluorogenic peroxidase substrate. Data are mean values of three experiments. HCA166 and HCA168 can be used interchangeably as cpature and detection antibodies in this bridging ELISA with a similar result.

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Herceptin® is a registered trademark of Genentech, Inc. HuCAL® is a registered trademark of Morphosys AG. QuantaBlu™ is a trademark of Thermo Fisher Scientific Inc. LYNX Rapid Conjugation Kit® is a registered trademark of Bio-Rad AbD Serotec Ltd.